After retreatment with EGFR-TKIs, 13 patients experienced progression, 12/13 (85.7%) of whom underwent re-biopsy at that time; the tumor biopsy sites were the lung, lymph node, bone, and pleura in 2/14 (14.3%) patients each, and liver in 1/14 (6.7%). Here, EGFR is linked to neoplasm.